high response rate when using a bispecific antibody to treat R/R multiple myeloma.

Published Date: 12 Apr 2024

71 percent ORR that increased over time, along with a good safety record when using linvoseltamab.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Retired Olympic athletes at greater risk of skin cancer and osteoarthritis, research reveals

2.

Three Cycles of Chemo Noninferior to Six for Rare Childhood Eye Cancer

3.

Celebrity Cancers Stoking Fear? Cisplatin Shortage Ends; Setback for Anti-TIGIT

4.

Year in Review: Non-Small Cell Lung Cancer

5.

Electronic Sepsis Alerts; Reducing Plaques in Coronary Arteries


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot